OptimizeRx Amends 8-K: Confirms Nasdaq Capital Market Listing
Ticker: OPRX · Form: 8-K/A · Filed: Jan 5, 2024 · CIK: 1448431
| Field | Detail |
|---|---|
| Company | Optimizerx CORP (OPRX) |
| Form Type | 8-K/A |
| Filed Date | Jan 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, amendment, stock-listing
TL;DR
**OptimizeRx just clarified its stock exchange listing on Nasdaq Capital Market.**
AI Summary
OptimizeRx Corp filed an 8-K/A Amendment No. 1 on January 5, 2024, to its original 8-K from October 20, 2023. This amendment clarifies that the company's Common Stock, with a $0.001 Par Value, is registered for trading on The Nasdaq Capital Market under the symbol OPRX. This matters to investors because it confirms the listing details of their shares, ensuring transparency and proper market identification for trading.
Why It Matters
This filing confirms the specific exchange where OptimizeRx stock (OPRX) is traded, providing clarity for investors and ensuring regulatory compliance.
Risk Assessment
Risk Level: low — This filing is an amendment for clarification and does not introduce new financial risks or operational changes.
Analyst Insight
A smart investor would note this filing as a routine regulatory update, confirming existing information rather than signaling a new investment opportunity or risk. It reinforces the company's compliance with listing requirements.
Key Numbers
- $0.001 — Par Value per Share (The stated par value of OptimizeRx's Common Stock.)
Key Players & Entities
- OptimizeRx Corporation (company) — the registrant filing the 8-K/A
- The Nasdaq Capital Market (company) — the exchange where OptimizeRx's Common Stock is registered
- $0.001 (dollar_amount) — the par value of OptimizeRx's Common Stock
- OPRX (company) — the trading symbol for OptimizeRx's Common Stock
- October 20, 2023 (date) — Date of Earliest Event Reported for the original 8-K
FAQ
What is the purpose of this 8-K/A filing by OptimizeRx Corporation?
This 8-K/A filing, Amendment No. 1, serves to amend the original 8-K filed on October 20, 2023, primarily to clarify information regarding the company's securities registered pursuant to Section 12(b) of the Act.
On which exchange is OptimizeRx Corporation's Common Stock registered for trading?
OptimizeRx Corporation's Common Stock, with a $0.001 Par Value, is registered on The Nasdaq Capital Market under the trading symbol OPRX.
What was the 'Date of Earliest Event Reported' for the original 8-K that this filing amends?
The 'Date of Earliest Event Reported' for the original 8-K was October 20, 2023.
What is the trading symbol for OptimizeRx Corporation's Common Stock?
The trading symbol for OptimizeRx Corporation's Common Stock is OPRX.
What is the par value of OptimizeRx Corporation's Common Stock?
The par value of OptimizeRx Corporation's Common Stock is $0.001.
Filing Stats: 857 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-01-05 17:19:24
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value OPRX The Nasdaq Capital M
Filing Documents
- ea191205-8ka1_optimizerx.htm (8-K/A) — 35KB
- ea191205ex23-1_optimizerx.htm (EX-23.1) — 2KB
- ea191205ex99-2_optimizerx.htm (EX-99.2) — 356KB
- ea191205ex99-3_optimizerx.htm (EX-99.3) — 178KB
- ea191205ex99-4_optimizerx.htm (EX-99.4) — 160KB
- ex23-1_001.jpg (GRAPHIC) — 7KB
- ex99-2_001.jpg (GRAPHIC) — 21KB
- ex99-2_002.jpg (GRAPHIC) — 7KB
- 0001213900-24-001616.txt ( ) — 1029KB
- oprx-20231020.xsd (EX-101.SCH) — 3KB
- oprx-20231020_lab.xml (EX-101.LAB) — 33KB
- oprx-20231020_pre.xml (EX-101.PRE) — 22KB
- ea191205-8ka1_optimizerx_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (a)
Financial Statements of Businesses Acquired
Financial Statements of Businesses Acquired (i) The audited balance sheets of Medicx as of December 31, 2022 and 2021, and the related statements of income, changes in stockholders' equity and cash flows for the fiscal years ended December 31, 2022 and 2021 are included as Exhibit 99.2 to this report and incorporated by reference herein. (ii) The unaudited balance sheets of Medicx as of June 30, 2023 and December 31, 2022 and the related statements of income, changed in stockholders' equity and cash flows for the three and six months ended June 30, 2023 and 2022 are included as Exhibit 99.3 to this report and incorporated by reference herein. (b) Pro Forma Financial Information OptimizeRx's unaudited pro forma combined balance sheet as of June 30, 2023 and pro forma condensed combined report and incorporated by reference herein. (d) Exhibits Exhibit Number Description 10.1*+ Common Stock Purchase Agreement dated October 24, 2023, by and among the Company and the Management Investors 23.1 Consent of UHY LLP 99.1++ Press Release of OptimizeRx dated October 25, 2023 99.2 Audited Financial Statements of Medicx as of December 31, 2022 and 2021 and for the fiscal years ended December 31, 2022 and 2021 99.3 Unaudited Financial Statements of Medicx as of June 30, 2023 and for the three and six months ended June 30, 2023 and 2022 99.4 Unaudited Pro Forma Combined Financial Information of OptimizeRx Corporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request. + Previously filed. ++ Previously furnished. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPTIMIZERX CORPORATION Date: January 5, 2024 By: /s/ Edward Stelmakh Name: Edward Stelmakh Title: Chief Financial Officer 3